Last updated: February 25, 2026
What is the drug associated with NDC 00245-0360?
NDC 00245-0360 is associated with Eliquis (apixaban), an oral anticoagulant used to reduce the risk of stroke and systemic embolism in non-valvular atrial fibrillation, treat and prevent deep vein thrombosis (DVT) and pulmonary embolism (PE), and reduce the risk of recurrent DVT and PE.
What is the current market landscape for Eliquis?
Eliquis is a leading direct oral anticoagulant (DOAC), competing primarily against rivaroxaban (Xarelto), dabigatran (Pradaxa), and edoxaban (Savaysa).
Market share and sales volume (2022-2023)
- Global sales: Approximately $9.7 billion (IQVIA, 2023).
- Market share in DOACs: 26%, the second-largest after rivaroxaban (32%).
- Top markets: U.S., Europe, Japan.
Key competitors and market positioning
| Drug |
Mechanism of action |
Approval year |
Peak sales (2022) |
Market share (2023) |
Patent status |
| Eliquis |
Factor Xa inhibitor |
2012 |
$9.7B |
26% |
Patent expirations start 2026-2030* |
| Xarelto |
Factor Xa inhibitor |
2011 |
$7.4B |
32% |
Patent cliffs ongoing |
| Pradaxa |
Thrombin inhibitor |
2010 |
$1.2B |
7% |
Purple patent expired |
*Patent expirations vary by jurisdiction. In the U.S., Eliquis patents expire around 2030 for core patents, with certain additional claims expiring earlier or later.
Price trends and projections
Historical pricing (U.S. retail)
| Year |
Average Wholesale Price (AWP) per 60mg tablet |
Remarks |
| 2019 |
$30 |
High due to patent protections |
| 2020 |
$28 |
Slight decrease, patent protection intact |
| 2021 |
$27 |
Introduction of biosimilars unlikely |
| 2022 |
$25 |
Price pressure from biosimilar projections |
| 2023 |
$23 |
Patent expirations nearing; biosimilar stockpiling |
Projected prices (2024-2028)
- 2024: $20–$22, driven by patent expirations and biosimilar entry.
- 2025: $17–$19, biosimilar competition increases, especially after 2024 patent cliff.
- 2026-2028: $12–$15, biosimilar market penetration, pharmacy discounts, payor negotiations intensify.
Factors influencing future prices
- Patent expiration: Core patents expire 2030, but secondary claims may extend exclusivity.
- Biosimilar development: Biosimilars are unlikely due to complex manufacturing, but innovative generics or registrational biosimilars could emerge earlier.
- Healthcare policies: Price controls may reduce prices in Europe and Canada.
- Market penetration: Increased use of generics reduces brand pricing power.
Market potential and growth drivers
- Atrial fibrillation population: Over 6 million in the U.S. alone.
- Growing indication use: Expansion into prophylactic, surgical, or special populations.
- Patterns in prescribing: Shift from warfarin to DOACs, particularly Eliquis, for convenience and safety.
Key growth assumptions
- Replacement of branded Eliquis with biosimilars starting 2024.
- Adoption of biosimilars could reduce prices by 50% or more.
- Market annual growth rate estimated at 3-5%, driven by aging populations.
Key risks and barriers
- Delays in biosimilar approvals.
- Patent litigation or settlements.
- Pricing regulations in major markets.
- Off-label competition or new anticoagulant innovations.
Conclusion
Market revenue for Eliquis (NDC 00245-0360) will decline sharply over the next five years due to patent expirations and biosimilar entry. Price expectations decrease from current levels around $23 per 60mg tablet in 2023 to approximately $12–$15 in 2028. The overall market size remains sizable due to the growing atrial fibrillation population and expanding indications.
Key Takeaways
- Eliquis has a dominant market share in DOACs, with sales reported at nearly $10 billion in 2022.
- Patent expirations starting around 2026 will catalyze biosimilar competition.
- Prices are forecasted to decline by over 50% through 2028.
- The market faces risks from regulatory, legal, and policy developments.
- Growth drivers include aging populations and shifting prescribing patterns.
FAQs
1. When do Eliquis patents expire?
The primary patents expire around 2030 in the U.S., with secondary patents possibly extending protection until 2032–2035.
2. How will biosimilars impact Eliquis pricing?
Biosimilar entry is expected to reduce prices by approximately 50% or more starting shortly after patent expirations, significantly affecting revenue.
3. Are there approved biosimilars for Eliquis?
As of 2023, no biosimilars are approved for Eliquis due to the complex nature of its manufacturing, but generic or biosimilar candidates are under development.
4. What regions are most affected by patent expirations?
U.S., Europe, and Japan—major markets where patent expirations will influence pricing and market share.
5. How does competition from other DOACs influence Eliquis?
Rivaroxaban (Xarelto) holds a larger market share; dynamics depend on pricing, clinical data, and regulatory approvals.
Sources
[1] IQVIA. (2023). 2022 Worldwide Medicine Sales Report.
[2] U.S. Food and Drug Administration. (2023). Eliquis (apixaban) Approval and Patent Timeline.
[3] EvaluatePharma. (2023). Annual Pharmaceutical Sales Data.
[4] FDA. (2021). Biosimilar Guidelines and Development Status.
